Moors & Cabot, Inc. Beam Therapeutics Inc. Transaction History

Moors & Cabot, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$36.73 - $51.6 $101,742 - $142,932	2,770 New	2,770 $108,000
Q2 2022 Aug 08, 2022	SELL	$29.86 - $62.36 $112,572 - $235,097	-3,770 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $6,802 - $9,906	100 Added 2.72%	3,770 $300,000
Q3 2021 Dec 08, 2021	SELL	$84.37 - $133.6 $534,062 - $845,688	-6,330 Reduced 63.3%	3,670 $320,000
Q3 2021 Nov 05, 2021	BUY	$84.37 - $133.6 $491,877 - $778,888	5,830 Added 139.81%	10,000 $96,000
Q2 2021 Aug 10, 2021	BUY	$64.12 - $128.71 $75,020 - $150,590	1,170 Added 39.0%	4,170 $537,000
Q4 2020 Feb 11, 2021	BUY	$22.24 - $95.63 $66,720 - $286,890	3,000 New	3,000 $246,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.